News | September 02, 2022
Ashland to expand bioresorbable polymers capacity in Ireland
The capital expansion program commenced in June 2022 and is expected to complete in 2024
The capital expansion program commenced in June 2022 and is expected to complete in 2024
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of US $282 million in the US
Carbamazepine Tablets are indicated for use as an anticonvulsant drug and in the treatment of the pain associated with true trigeminal neuralgia
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Lupin is the 6th largest company in the Indian Pharmaceutical Market
he US FDA has issued six observations pursuant to the completion of the audit.
Subscribe To Our Newsletter & Stay Updated
